Immunotherapy with Intravenous Immunoglobulins

Content: 
Front Matter, Page iii
Copyright, Page iv
Contributors, Pages v-xii
Preface, Pages xix-xx, P. Imbach
IVIG and regulation of autoimmunity through the idiotypic network, Pages 3-14, G. DIETRICH, F. ROSSI, Y. SULTAN, S. KAVERI, U.E. NYDEGGER, M.D. KAZATCHKINE
Intravenous immunoglobulin: mechanisms of action and their clinical application, Pages 15-25, A.C. NEWLAND, M.G. MACEY, P.A. VEYS
Hypothetic and established action mechanisms of therapy with immunoglobulin G, Pages 27-36, URS E. NYDEGGER
The distribution and catabolism of IVIG preparations in immunodeficient patients, Pages 37-45, RALPH J. WEDGWOOD
The home administration of IVIG in children with primary immunodeficiency, Pages 47-56, ROGER H. KOBAYASHI, AI LAN D. KOBAYASHI, NAPOLEON LEE, SUSANNA FISCHER, HANS D. OCHS
IVIG can save many preterm infants, Pages 59-64, G. ROBERTO BURGIO
Neonatal sepsis: an overview, Pages 65-74, CAROL J. BAKER
Immunoglobulin treatment and prophylaxis in the neonate, Pages 75-92, A.G. UGAZIO, G. CHIRICO, M. DUSE, A. PLEBANI, L.D. NOTARANGELO, G. RONDINI, G.R. BURGIO
Intravenous immunoglobulin in neonates: a decade of experience, Pages 93-101, GERALD W. FISCHER, LEONARD E. WEISMAN
Passive immunization for the protection of infants and young children from respiratory infection by respiratory syncytial virus, Pages 103-112, VAL G. HEMMING, GREGORY A. PRINCE
Use of immunoglobulin therapy in secondary antibody deficiencies, Pages 115-126, E. RICHARD STIEHM
Immunoprophylaxis in “septic-risk” patients undergoing surgery for gastrointestinal cancer. Preliminary results of a randomized, controlled, multicenter clinical trial, Pages 127-139, FERDINANDO CAFIERO, MARCO GIPPONI
Non-specific immunotherapy and intravenous gammaglobulin administration in surgical sepsis, Pages 141-147, L. DOMINIONI, A. BENEVENTO, R. GENNARI, M.C. BESOZZI, M. HOURCADE, R. DIONIGI, M. ZANELLO
Control of infection following major burns: the immunological approach, Pages 149-163, ANDREW M. MUNSTER
IVIG indication in patients with low-grade B-cell tumors, Pages 165-172, HELEN CHAPEL, HELEN GRIFFITHS, MARTIN LEE
Frequency and pathogenic implication of reactivated lymphotropic herpesviruses in autoimmune and immune deficiency disorders, Pages 173-192, GERHARD R.F. KRUEGER, DHARAM V. ABLASHI, ALBERT RAMON, UWE LEMBKE
Viruses and immunodeficiency, Pages 193-200, A.D.B. WEBSTER, A. SA'ADU
The role of IVIG in pediatric HIV infection, Pages 201-209, URS B. SCHAAD
Intravenous immunoglobulin in marrow transplantation, Pages 211-217, NEENA KAPOOR
Intravenous immunoglobulin for cytomegalovirus pneumonia, Pages 219-228, GERALD ELFENBEIN, JEFFREY KRISCHER, JOHN GRAHAM-POLE, RICHARD HONG, JAN JANSEN, HILLARD LAZARUS, ELLIOT WINTON, RONALD BABINGTON
The effect of prophylactic immune globulin on cytomegalovirus infection in liver transplants, Pages 229-235, JOSEPH B. COFER, CHRISTINE A. MORRIS, BO S. HUSBERG, ROBERT M. GOLDSTEIN, THOMAS A. GONWA, GORAN B. KLINTMALM, WILLIAM L. SUTKER
New clinical aspects of immune thrombocytopenic purpura (ITP), Pages 239-243, P. IMBACH
Intravenous immunoglobulin: new aspects of mechanism of action in chronic ITP, Pages 245-252, PETER BERCHTOLD, ROBERT McMILLAN
Treatment effects on chronic idiopathic thrombocytopenia purpura, Pages 253-259, JAMES B. BUSSEL
Kawasaki disease and IVIG: what's going on here?, Pages 261-268, STANFORD T. SHULMAN
High-dose intravenous immunoglobulin therapy for insulin-dependent diabetes mellitus, Pages 269-282, GARY M. LEONG, ZOE THAYER, GABRIEL ANTONY, STEPHEN COLAGIURI, JOHN DWYER, WARREN KIDSON, RICHARD FISHER, DENIS WAKEFIELD
Effect of high-dose intravenous immunoglobulin in rheumatoid arthritis, Pages 283-295, A. CORVETTA, M.M. LUCHETTI, G. POMPONIO, G. DANIELI, P.J. SPAETH
Therapeutic opportunities in systemic vasculitis, Pages 297-306, C.M. LOCKWOOD
Ageing and autoimmunity: lessons learnt from the presence of autoantibodies in patients with malignant conditions, Pages 307-316, YEHUDA SHOENFELD
New concepts in the pathogenesis of allergies and asthma, Pages 319-331, GARY L. LARSEN, BRUCE D. MAZER, ERWIN W. GELFAND
Induction of immune tolerance in hemophiliacs with inhibitors, by combined treatment with IVIG, cyclophosphamide and factor VIII or IX–the Malmö model, Pages 333-344, INGAMARIE NILSSON, ERIK BERNTORP
Combined use of plasmapheresis and intravenous gammaglobulin in the treatment of HIV-positive and HIV-negative autoimmune syndromes, Pages 345-349, RAPHAEL B. STRICKER, DOBRI D. KIPROV
IVIG treatment in chronic inflammatory demyelinating polyneuropathy, Pages 351-358, M. VERMEULEN, P.A. van DOORN, I. LUNDKVIST, A. BRAND
Intravenous immunoglobulin in idiopathic inflammatory bowel disease: results of an open-label therapeutic trial, Pages 359-376, HANS D. OCHS, SUSANNA H. FISCHER, DENNIS L. CHRISTIE, RODGER C. HAGGITT, DOUGLAS S. LEVINE
The response of patients with chronic fatigue syndrome to intravenously administered gammaglobulin, Pages 377-386, J.M. DWYER, A.R. LLOYD, I.B. HICKIE, D. WAKEFIELD, C.R. BOUGHTON
Intravenously administered IgG for the treatment of thyroid eye disease, Pages 387-394, J.M. DWYER, ELIZABETH M. BENSON, J.N. CURRIE, J. O'DAY
The use of IVIG for the treatment of recurrent spontaneous abortion, Pages 395-400, C. COULAM, A. PETERS, J. McINTYRE, W. FAULK
Immunodeficiency in Down's syndrome, Pages 401-423, A. FERRANTE, L.J. BEARD, Y.H. THONG, V. VUDDHAKUL, B. ROWAN-KELLY, D. GOH, G.T. MAI, R.K.S. LOH, S.C. HARTH, C. PEARSON, D. ROBERTON
Maximizing the therapeutic potential of intravenously administered immunoglobulin G, Pages 427-432, JOHN M. DWYER
PRIMARY IMMUNODEFICIENCY, Pages 435-438
NEONATAL INFECTIONS, Pages 438-444
HIV INFECTION, Pages 444-446
TOLERABILITY AND SAFETY, Pages 446-448
SECONDARY IMMUNODEFICIENCY, Pages 448-453
AUTOIMMUNITY, Pages 453-461
MISCELLANEOUS, Pages 461-472
Index, Pages 473-484